

Are proud to present: Dr. Roger Bossé

“Solutions to perform ultra sensitive homogeneous detection of intracellular and blood-borne markers”

Friday 29/8/2008, 2:00 PM to 3:30 PM

Room 102, Building E6A, Macquarie University, North Ryde

RSVP: Thursday 28/08/08

Large Pharma companies screen recurrently many millions of compounds across multiple therapeutic targets to find new drug candidates. Since screening campaigns are limited in both budget and time, companies need to rely on industrialized R&D processes involving high-throughput screening (HTS) assay technologies to attain their goals. HTS assay technologies must be sensitive, robust, reproducible, automatable and miniaturizable while staying cost effective.

Because most of the traditional biochemical assays involving purified targets are being replaced by more biologically relevant cellular assays, HTS technologies must be capable of detecting endogenous levels of second messengers or other cellular biomarkers (i.e. phosphoproteins, etc). All these technical attributes make HTS technologies more and more attractive to research groups acting outside an industrial HTS environment; namely those involved in academic research. During this seminar, examples involving PerkinElmer assay technologies developed to measure the activity of G-protein coupled receptors (e.g. LANCE cAMP, Ca²⁺ sensitive Photoproteins) and kinases (e.g. AlphaScreen, SureFire) in a cellular context will be presented as well as customer cases studies showing the benefits of using AlphaLISA, an evolved version of AlphaScreen based on Europium emission, to perform ultrasensitive detection of biomarkers in complex assay medium including tissue homogenates and serum.

Roger Bossé, Ph.D.

Technology and Business Development Manager

Bio-discovery, PerkinElmer LAS Inc.

Career Highlights:

- ❖ Post-doctoral fellowships at CHUL Research Center, Canada with Dr. Di Paolo; and Duke University Medical Center, USA with Dr. Caron; after being awarded his PhD from Sherbrooke University;
- ❖ Responsible for the AlphaScreen R&D program (1999-2001) and developed 19 different products and more than 50 HTS assays in 3 years;
- ❖ Currently the Technology & Business Development Manager, Molecular Medicine Business Unit in 2006;
- ❖ Co-chair, 13th Annual Society of Biomolecular Sciences Conference & Exhibition Meeting, Montreal (2007);
- ❖ Elected on the Society of Biomolecular Sciences Board of Directors for a 3 year term (2008).

For further information or to RSVP, please contact:

Peter Jenkins: Ph 0409 562 537
peter.jenkins@perkinelmer.com

OR

Leah Boucher: Ph 9850 4169
lboucher@ics.mq.edu.au